Codiak BioSciences, a venture-backed start-up in Cambridge, Mass, has appointed Ariel Jasie as Chief Business Officer, Linda Bain as CFO and Konstantin Konstantinov as Senior Vice President.
“They all bring critical expertise and leadership experience to Codiak as we build our leadership position in the development of therapeutic and diagnostic exosomes,” said Doug Williams, Codiak’s president and CEO, who was appointed last November, after leading R&D at Biogen. “Jasie has deep experience building organizations through strategic deal-making; Bain brings extensive financial, operational, and capital markets experience; and Konstantinov has pioneered disruptive innovation to improve biomanufacturing,” he added.
Codiak, a firm dedicated to the field of exosome biology, recently closed the first portion of an over USD80 million Series A and B financing. ARCH Venture Partners, Flagship Ventures, Fidelity Management and Research Company, the Alaska Permanent Fund and Alexandria Venture Investments are members of the funding syndicate.
Jasie joined from Celgene Corporation, where he led the Strategy and Operations Group in the Research and Early Development franchise. He previously served on the Celgene Business Development team, leading numerous deals including M&A, in-licensing, collaborations, strategic equity investments, seeding, syndicating and constructing “build to buys,” and serving as Board Observer to certain collaboration partners/equity investments.
Prior to Codiak, Bain worked as CFO at Avalanche Biotechnologies, where she led a successful IPO and follow-on financing. She previously served as vice president of finance, business operations and treasurer at Bluebird Bio, where her tenure included a Series D financing and IPO.
Previously, Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub. Prior to this, Konstantinov worked for Bayer in Berkeley, Calif. for 14 years, advancing to the position of Head of Process Sciences.